Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III SLIT vs placebo in pediatric grass pollen allergic rhinoconjunctivitis
2006-003006-26Phase 3Completed
- Sponsor
- Stallergenes Greer
- Start
- Sep 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and allergic rhinitis (AR) comparing SLIT grass pollen allergen extract with Placebo (2 arms). Primary endpoint: Average Rhinoconjunctivitis Total Symptom Score (RTSS) while on treatment. Started Sep 2006; status: completed.
02
Drugs
Oralair
03
Conditions
allergic rhinoconjunctivitis (ARC)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2006-003006-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003006-26.